Skip to main content
Equibles
AMPH logo

AMPH · Amphastar Pharmaceuticals, Inc.

Track AMPH — free

Use AMPH with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about AMPH

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$21.74 +0.40 (+1.87%) At close · Aug 19
Market Cap
$907.76M
Shares
42.54M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$21.74 Open$21.64 Day$21.15–21.99 52W close$16.87–30.81 Avg vol 30d457K Short int4.9M · 11.6% float · 11.9d Short vol69% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Buy Momentum Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg −4%
      below
      Price vs 50-day avg +9%
      above
      RSI (14) 64
      neutral
      MACD trend Positive
      52-week position 35%
      mid-range
      Momentum
      relative strength
      Weak
      1-month return +13%
      trailing
      6-month return −18%
      trailing
      YTD return −19%
      this year
      Relative strength −30%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $20 › 200d $23 — 200d above 50d
      Institutional flow Distributing
      -3% holders QoQ · +33 funds added
      Insider flow Distributing
      Net -$161.9K over 90 days · 100% sells
      Short interest Rising
      11.59% of float · ▲ +18.1% MoM · 11.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      208 holders — near 3-yr low, contrarian setup
      Squeeze score 86
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth −2%
      Y/Y
      Gross margin 49%
      contracting
      EPS growth −34%
      Y/Y
      Free cash flow $121.2M
      Valuation P/E 12.6
      below peers
      Buyback $485.0M
      authorized
      Balance sheet $120.0M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 51%
      annualized · 1-yr
      Max drawdown −45%
      past year
      ATR 3.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Prior guidance period ended · from the Earnings Call filed Dec 31, 2023
      Primatene MIST sales · this year $100M
      Capital spending on Rancho Cucamonga expansion project · 2025 $40M
      Increased SG&A costs as a percentage of BAQSIMI revenue · this year 17%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −4% Neutral
      Price vs 50-day avg
      +9% Bullish
      RSI (14)
      64 Neutral
      MACD trend
      Positive Bullish
      52-week position
      35% Neutral
      Market signals — smart money & positioning
      Bearish · 3 of 6
      Trend (MA cross) No cross
      50d $20 › 200d $23 — 200d above 50d
      Institutional flow Distributing
      -3% holders QoQ · +33 funds added
      Insider flow Distributing
      Net -$161.9K over 90 days · 100% sells
      Short interest Rising
      11.59% of float · ▲ +18.1% MoM · 11.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      208 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      Range low $17 Now $22 · 35% Range high $31
      vs 200-day avg -4% vs 50-day avg +9%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      AMPH
      Amphastar Pharmaceuticals, Inc.
      this stock
      		$907.76M -18.8% -1.7% 12.6 11.6%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      		 $64.91B — — — 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      		 $57.75B +17.6% — — 0.1%
      GALDY
      Galderma Group AG/ADR
      		 $50.24B +4.0% — — 0.0%
      HLN
      Haleon plc
      		 $43.41B -2.4% — — 0.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      208
      % held
      66.5%
      Net QoQ
      -4.2M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      273
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      4.9M
      Days to cover
      11.9d
      Change
      +753.9K sh
      View
      Short Volume
      Short vol %
      69%
      As of
      Aug 19, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.0K
      Value
      $39.4K
      As of
      Jul 29, 2026
      View
      Off-Exchange
      Off-exchange %
      37.1%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$161.9K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $719.9M
      Net income (FY)
      $98.1M
      EPS diluted
      $2.03
      View
      Buybacks
      Authorized
      $485.0M
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      15
      View
      Proposed Sales
      Value
      $989.1K
      Shares
      47.1K
      Filed
      Aug 18, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      AMPH +8.8% +12.6% -17.9% +9.0% -18.8%
      SPY -0.4% +2.9% +11.6% +3.0% +12.8%
      vs SPY +9.3% +9.7% -29.5% +6.1% -31.6%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $485.00M
      Spent (derived)
      —
      Remaining
      —

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1297184 CUSIP 03209R103 13F (30d) 186 filings 186 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)